Skip to main content
OpenTrials
Completed

NCT Number: NCT02990455

Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder

The proposed research will investigate whether smokers with vs. without current at-risk alcohol drinking (ARD) respond to reduced nicotine cigarettes by increasing their alcohol consumption or smoke exposure, thereby diminishing the hypothesized public health benefit of these new products.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Battelle Memorial Institute

Baltimore, Maryland, 21209, United States

About this study

The current proposal examines response to two RNCs, one with low nicotine content (RNC Low; 0.03mg) and one with moderate nicotine content (RNC Moderate; 0.8mg) in daily smokers with and without ARD. Participants (N = 70) will attend a total of five visits to the laboratory. The first visit will be to classify participants as either ARD (n = 35) or Non ARD (n = 35) and gather baseline data. Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette. On the first and last day of each of the two experimental conditions, participants will smoke the assigned RNC in the laboratory, and data on toxicant exposure (i.e., boost in exhaled carbon monoxide and plasma nicotine and cotinine; solanesol from smoked cigarette butts), subjective acceptability (i.e., subjective response; risk perceptions; relative reinforcing efficacy); and smoking compensation (i.e., smoking topography measures) related to the smoked RNC will be collected. During each 7-day period of exposure to the RNCs, participants will provide daily data on alcohol and nicotine use, nicotine withdrawal, smoking urge, and alcohol urge via telephone-based Interactive Voice Response technology. The strength of our study design is that we can evaluate both between-group (i.e., ARD vs. Non ARD) and within-person (i.e., RNC Low vs. Moderate) differences in response to RNCs and, furthermore, can examine whether increased nicotine withdrawal, smoking urge, and alcohol urge mediate the relation between decreased nicotine exposure and alcohol consumption. Results from this study will show what mechanisms underlying drinking and smoking may need to be addressed in future integrated interventions for both problems and will immediately inform the practical implementation of market-wide reductions in cigarette nicotine content among smokers with ARD.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 21-65;
  • Smokes ≥ 10 cigarettes/day for ≥ 2 years;
  • Has no immediate plans to quit drinking or smoking; and
  • Sufficient understanding of informed consent form and study procedures.

Exclusion criteria

  • Has or is at-risk of serious alcohol-related consequences, defined as any of the following:
  • Meets DSM-5 criteria for current alcohol use disorder with the presence of 6 or more symptoms (i.e., current severity of severe)
  • Has a Clinical Institute Withdrawal Assessment scale score of ≥8,
  • Self-report of history of seizures, delirium, or hallucinations during alcohol withdrawal;
  • Self-report of drinking to avoid withdrawal symptoms, or
  • Self-report of a history of alcohol withdrawal treatment.
  • Women if pregnant, lactating, or not using a reliable form of birth control;
  • Has current serious psychiatric disorder;
  • Has DSM-5 current severe substance use disorder, other than nicotine;
  • Has current use of smokeless tobacco, pipes, cigars, e-cigarettes, or nicotine replacement products;
  • Displays clinically evident intoxication on any study visit, confirmed by breathalyzer test (breath alcohol level (BAL)>0.02 mg%);
  • Has difficulties with blood draws or poor venous access; or
  • Has significant smoking-related disease (by history).

Treatment and study plan

Reduced Nicotine Cigarettes

Drug

Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.

Other names: Nicotine research cigarettes

Primary outcomes

  1. Alcohol drinks per day

    Time frame: 7 days

Secondary outcomes

  1. Toxicant exposure

    Time frame: 7 days

    (1) boost in (a) exhaled carbon monoxide, (b) plasma nicotine, and (c) plasma cotinine, and (2) solanesol after laboratory smoking

  2. Subjective acceptability

    Time frame: 7 days

    subjective response

  3. Smoking compensation

    Time frame: 7 days

    number of cigarettes per day during each 7-day period

Sponsors and collaborators

Lead sponsor

Battelle Memorial Institute

Other

Registry information

Acronym: RedNic

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Dec 13, 2016
Registry last updated
Sep 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.